Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

Next Previous
Trial Profile

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daraxonrasib (Primary) ; Elironrasib (Primary)
  • Indications Lung cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms RMC6291-101
  • Sponsors REVOLUTION Medicines

Most Recent Events

  • 02 Dec 2024 According to a Revolution Medicines media release, company announced key clinical data updates from this study to be presented during an investor webcast today at 8:00 a.m. Eastern Time (ET).
  • 02 Dec 2024 Results(As data cutoff date October 28, 2024, n=74) published in the REVOLUTION Medicines Media Release.
  • 07 Aug 2024 According to a Revolution Medicines media release, company expects to disclose initial clinical PK, safety, tolerability and antitumor activity data for combination of RMC-6291 with RMC-6236 in the fourth quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top